IFNA1 and hereditary clear cell renal cell carcinoma: Furthermore, clinical trials have demonstrated that IFN α also exerts its therapeutic mechanisms against other tumor types, including renal cell carcinoma, Kaposi's sarcoma, and melanoma [13].